DOCSLIB.ORG

Refractory Helicobacter Pylori Gastritis: the Hidden Predictors Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Refractory Helicobacter Pylori Gastritis: the Hidden Predictors Of Journal of Global Antimicrobial Resistance 19 (2019) 194–200 Contents lists available at ScienceDirect Journal of Global Antimicrobial Resistance journal homepage: www.elsevier.com/locate/jgar Refractory Helicobacter pylori gastritis: The hidden predictors of resistance Amr Shaaban Hanafy*, Waseem M. Seleem Internal Medicine Department, Endoscopy Unit, Gastroenterology and Hepatology Division, Zagazig University, Zagazig, Sharqia 44519, Egypt A R T I C L E I N F O A B S T R A C T Article history: Objectives: Failure of Helicobacter pylori eradication is documented in 20% of patients. Some patients show Received 15 February 2019 a negative faecal antigen test (FAT) with persistent symptoms after therapy. The aim of this study was to Received in revised form 3 May 2019 detect occult H. pylori infection in patients with persistent symptoms despite FAT negativity following Accepted 9 May 2019 therapy. Available online 18 May 2019 Methods: A total of 200 symptomatic patients presenting with dyspepsia and positive FAT were treated with H. pylori triple therapy for 2 weeks. Refractory patients received levofloxacin-based salvage therapy. Keywords: Upper gastrointestinal endoscopy was performed for patients with persistent symptoms despite negative Refractory infection FAT after salvage therapy. Gastric biopsies were exposed to rapid urease test and RFLP-PCR for Faecal antigen test clarithromycin resistance in domain V of 23S rRNA (2142/2143 point mutations) as well as culture and Clarithromycin resistance Helicobacter pylori antimicrobial susceptibility testing (AST). Culture Results: A total of 136 patients responded to classic triple therapy with negative FAT, and 15 patients showed persistent symptoms with positive FAT and received salvage therapy. The remaining 49 patients showed persistent symptoms despite negative FAT, therefore gastric biopsies with rapid urease test were performed. Clarithromycin resistance was confirmed in 12/49 patients (24.5%). Cultures were most commonly susceptible to norfloxacin (n = 18), moxifloxacin (n = 13), doxycycline (n = 11) and amikacin (n = 8). Non-responders with negative FAT had moderate or severe fatty liver disease (26.5% and 32.7%, respectively), 40.9% had hepatitis C virus (HCV) infection, and they had significantly higher HOMA-IR and HbA1c. Conclusion: Diabetes mellitus, HCV and non-alcoholic fatty liver disease predispose to refractory H. pylori requiring culture and AST. © 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved. 1. Introduction acid secretion and the development of intestinal metaplasia, glandular atrophy and hypochlorhydria [5]. Helicobacter pylori is considered a public-health problem as it is Pathogenic factors of H. pylori are the presence of flagella, involved in the development of duodenal and gastric ulcers, gastric urease enzyme production, mucosal adherence by bacterial cancer, gastric mucosa-associated lymphoid tissue (MALT) lym- adhesin (BabA), mediation of tissue injury by lipopolysaccharide phoma and gastric adenocarcinoma [1]. that interacts trefoil factor 1 to promote colonisation, effector H. pylori is a flagellate, Gram-negative, spiral-shaped bacterium protein cytotoxin-associated gene A (CagA), vacuolating cytotoxin with microaerophilic behaviour [2,3]. Infection with H. pylori is (VacA), outer inflammatory protein (OipA) and duodenal ulcer- commonly acquired during childhood and the methods of promoting protein A (DupA). transmission are mainly person-to-person and interfamilial [4]. In addition, H. pylori reduces the production of heat shock Acid secretion is increased in antrum-predominant gastritis, proteins leading to immune evasion with long-term colonisation whereas corpus-predominant gastritis is characterised by reduced [6]. The predominant immunological mechanisms in H. pylori infection are the Th1 immune response triggered by interleukin 12 (IL-12) and IL-18 following H. pylori antigen presentation and recognition by gastric epithelial cells, dendritic cells and macrophages with enhanced production of Th1-dominated * Corresponding author. cytokines such as tumour necrosis factor-alpha (TNFα), IL-1β E-mail addresses: [email protected], [email protected] (A.S. Hanafy). and interferon-gamma (IFNg) [7]. https://doi.org/10.1016/j.jgar.2019.05.015 2213-7165/© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved. A.S. Hanafy, W.M. Seleem / Journal of Global Antimicrobial Resistance 19 (2019) 194–200 195 Mechanisms of refractory H. pylori are the presence of Declaration of Helsinki as reflected in a priori approval by the clarithromycin- and metronidazole-resistant strains (30% and institution’s Human Research Committee. 30–60% of cases, respectively) [8], previous macrolide experience, patient non-compliance, and failure of adequate acid suppression 2.2. Biochemical investigations that promotes H. pylori to become more susceptible to antimicro- bial therapy [9]. 2.2.1. Laboratory investigations Although classic triple therapy is effective, it is associated with The following laboratory investigations were performed: liver treatment failure in 20–30% of patients [10] or even higher in real- and kidney function tests; complete blood count; fasting and life clinical practice [11,12]. postprandial blood glucose; HbA1c level; and fasting insulin, H. pylori shows oncogenic behaviour. Eradication reduces the which was measured quantitatively by electrochemiluminescence gastric cancer incidence by 39% and reverses atrophic gastritis in immunoassay with a cut-off value 8.64 mIU/mL. 50%, therefore confirmed H. pylori infection should be treated even Insulin resistance was calculated by Homeostatic Model in asymptomatic patients [13,14]. Assessment of Insulin Resistance (HOMA-IR) using the following Poor glycaemic control had been found to increase the risk formula: fasting glucose (mg/dL) Â fasting insulin (mIU/mL)/405; a of persistence and the carcinogenic effect of H. pylori. Ikeda value >2 indicates insulin resistance [18,19]. et al. reported a greater risk of gastric cancer in those with high haemoglobin A1c (HbA1c) 6% and co-existent H. pylori infection 2.2.2. Association with other infections [15]. The possible association of other infections in resistant cases of Chronic hepatitis C virus (HCV) infection is associated with H. pylori was determined by detection of HCV antibody for HCV H. pylori in nearly 40% of patients. Its possible localisation in the infection and hepatitis B surface antigen (HBsAg) for hepatitis B gastric microenvironment might induce the persistence of H. pylori virus (HBV) infection. Cases with positive serology underwent and may trigger the occurrence of gastric non-Hodgkin's quantitative PCR. lymphoma [16]. The aim of the current study was to determine the incidence of 2.2.3. Monoclonal H. pylori faecal antigen test (FAT) occult H. pylori infection in gastric biopsies obtained by upper Stool samples (100 mL) were tested using enzyme immunoas- gastrointestinal endoscopy in patients with persistence of say kits (ACON Laboratories Inc., San Diego, CA, USA) according to symptoms following classic triple therapy despite a negative the manufacturer’s instructions. Positive H. pylori infection status faecal antigen test (FAT). was determined as an H. pylori stool antigen 55 ng/mL. The inter- and intra-assay coefficients of variation of the assay were 2. Materials and methods both <5%. The test was performed 6 weeks after first-line or salvage therapy. 2.1. Patient selection 2.3. Abdominal ultrasound This was an observational study conducted from May 2016 to June 2018 in the Gastroenterology Outpatient Clinic and Endosco- Patients with refractory H. pylori were examined for other py Unit of the Internal Medicine Department of Zagazig University causes of dyspepsia and abdominal pain such as fatty liver disease, Hospital, which is a tertiary referral centre in Zagazig, Egypt. A total liver cirrhosis, gallstones and pancreatic disorders. of 200 patients with epigastric pain and dyspepsia with positive FAT for H. pylori were treated with tripe therapy of esomeprazole 2.4. Upper gastrointestinal endoscopy 40 mg once daily, amoxicillin 1 g twice daily and clarithromycin 500 mg twice daily for 2 weeks. A minimum of four biopsy specimens were obtained from the Patients were evaluated by taking a complete history, physical proximal and distal stomach to establish histological H. pylori examination and symptom assessment by the Quality of Life in eradication, as infection mostly had a patchy localisation. Reflux and Dyspepsia (QOLRAD) questionnaire, which is composed of five domains: emotional distress (score, 6–41); sleep distur- 2.5. Rapid urease test bance (score, 5–35); vitality (score, 3–21); food/drink problems (score, 6–40); and social/physical functioning (score, 5–35), giving The rapid urease test, also know as the CLO (Campylobacter-like a total possible score of 25–172, with a lower value indicating a organism) test, detects the presence of urease in the gastric more severe impact on daily activities [17]. mucosa. The rapid urease test was performed during endoscopy Patients with persistent symptoms as assessed by QOLRAD and and the tissue was placed into a medium containing urea and a persistently positive FAT performed 6 weeks after finishing first- colour indicator; yellow (negative) and red (positive) discolor- line therapy underwent abdominal ultrasound to rule out more ations were assigned. The rapid urease test was performed
Load more

Recommended publications
  • Dyspepsia (Indigestion)
    Indigestion (dydpepsia). Indigestion information - Patient | Patient Page 1 of 5 View this article online at https://patient.info/health/dyspepsia-indigestion Dyspepsia (Indigestion) Dyspepsia (indigestion) is a term which describes pain and sometimes other symptoms which come from your upper gut (the stomach, oesophagus or duodenum). There are various causes (described below). Treatment depends on the likely cause. Understanding digestion Food passes down the gullet (oesophagus) into the stomach. The stomach makes acid which is not essential but helps to digest food. Food then passes gradually into the first part of the small intestine (the duodenum). In the duodenum and the rest of the small intestine, food mixes with chemicals called enzymes. The enzymes come from the pancreas and from cells lining the intestine. The enzymes break down (digest) the food. Digested food is then absorbed into the body from the small intestine. What is dyspepsia? Dyspepsia is a term which includes a group of symptoms that come from a problem in your upper gut. The gut (gastrointestinal tract) is the tube that starts at the mouth and ends at the anus. The upper gut includes the oesophagus, stomach and duodenum. Various conditions cause dyspepsia. The main symptom is usually pain or discomfort in the upper tummy (abdomen). In addition, other symptoms that may develop include: • Bloating. • Belching. • Quickly feeling full after eating. • Feeling sick (nausea). • Being sick (vomiting). Symptoms are often related to eating. Doctors used to include heartburn (a burning sensation felt in the lower chest area) and bitter-tasting liquid coming up into the back of the throat (sometimes called 'waterbrash') as symptoms of dyspepsia.
    [Show full text]
  • Abdominal Pain - Gastroesophageal Reflux Disease
    ACS/ASE Medical Student Core Curriculum Abdominal Pain - Gastroesophageal Reflux Disease ABDOMINAL PAIN - GASTROESOPHAGEAL REFLUX DISEASE Epidemiology and Pathophysiology Gastroesophageal reflux disease (GERD) is one of the most commonly encountered benign foregut disorders. Approximately 20-40% of adults in the United States experience chronic GERD symptoms, and these rates are rising rapidly. GERD is the most common gastrointestinal-related disorder that is managed in outpatient primary care clinics. GERD is defined as a condition which develops when stomach contents reflux into the esophagus causing bothersome symptoms and/or complications. Mechanical failure of the antireflux mechanism is considered the cause of GERD. Mechanical failure can be secondary to functional defects of the lower esophageal sphincter or anatomic defects that result from a hiatal or paraesophageal hernia. These defects can include widening of the diaphragmatic hiatus, disturbance of the angle of His, loss of the gastroesophageal flap valve, displacement of lower esophageal sphincter into the chest, and/or failure of the phrenoesophageal membrane. Symptoms, however, can be accentuated by a variety of factors including dietary habits, eating behaviors, obesity, pregnancy, medications, delayed gastric emptying, altered esophageal mucosal resistance, and/or impaired esophageal clearance. Signs and Symptoms Typical GERD symptoms include heartburn, regurgitation, dysphagia, excessive eructation, and epigastric pain. Patients can also present with extra-esophageal symptoms including cough, hoarse voice, sore throat, and/or globus. GERD can present with a wide spectrum of disease severity ranging from mild, intermittent symptoms to severe, daily symptoms with associated esophageal and/or airway damage. For example, severe GERD can contribute to shortness of breath, worsening asthma, and/or recurrent aspiration pneumonia.
    [Show full text]
  • Gastritis - Symptoms and Causes - Mayo Clinic Visited 11/22/2019
    Gastritis - Symptoms and causes - Mayo Clinic Visited 11/22/2019 Request an Appointment Find a Doctor MENU Find a Job Give Now Log in to Patient Account English Patient Care & Health Information Diseases & Conditions Request an Gastritis Appointment Symptoms & causes Diagnosis & treatment Doctors & departments Overview Print Advertisement Gastritis is a general term for a group Mayo Clinic does not endorse companies or of conditions with one thing in common: products. Advertising revenue supports our not- inflammation of the lining of the for-profit mission. stomach. The inflammation of gastritis Advertising & Sponsorship is most often the result of infection with Policy Opportunities Ad Choices the same bacterium that causes most stomach ulcers. Regular use of certain Stomach and pain relievers and drinking too much pyloric valve Mayo Clinic Marketplace alcohol also can contribute to gastritis. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic. Gastritis may occur suddenly (acute gastritis), or appear slowly over time (chronic gastritis). In some cases, gastritis NEW – Guide to Fibromyalgia can lead to ulcers and an increased risk of stomach cancer. Instant access – Mayo Clinic Health Letter For most people, however, gastritis isn't serious and improves quickly with treatment. Diabetes? This diet works … Stop osteoporosis in its tracks The Mayo Clinic Diet Online Products & Services Book: Mayo Clinic on Digestive Health https://www.mayoclinic.org/diseases-conditions/gastritis/symptoms-causes/syc-20355807[11/22/2019 4:16:25 PM] Gastritis - Symptoms and causes - Mayo Clinic Visited 11/22/2019 Symptoms The signs and symptoms of gastritis include: Gnawing or burning ache or pain (indigestion) in your upper abdomen that may become either worse or better with eating Nausea Vomiting A feeling of fullness in your upper abdomen after eating Gastritis doesn't always cause signs and symptoms.
    [Show full text]
  • Primary Biliary Cholangitis: a Brief Overview Justin S
    REVIEW Primary Biliary Cholangitis: A Brief Overview Justin S. Louie,* Sirisha Grandhe,* Karen Matsukuma,† and Christopher L. Bowlus* Primary biliary cholangitis (PBC), previously referred to supported by the higher concordance of PBC in monozy- as primary biliary cirrhosis, is the most common chronic gotic compared with dizygotic twins.4 In addition, certain cholestatic autoimmune disease affecting adults in the human leukocyte antigen haplotypes have been associ- United States.1 It is characterized by a hallmark serologic ated with PBC, as well as variants at loci along the inter- signature, antimitochondrial antibody (AMA), and specific leukin-12 (IL-12) immunoregulatory pathway (IL-12A and bile duct pathology with progressive intrahepatic duct de- IL-12RB2 loci).5 struction leading to cholestasis. PBC is potentially fatal and can have both intrahepatic and extrahepatic complications. PATHOGENESIS EPIDEMIOLOGY The primary disease mechanism in PBC is thought to be T cell lymphocyte–mediated injury against intralobu- PBC affects all races and ethnicities; however, it is best lar biliary epithelial cells. This causes progressive destruc- studied in the Caucasian population. The condition pre- tion and eventual disappearance of the intralobular bile dominantly affects women older than 40 years, with a ducts. Molecular mimicry has been proposed as the ini- female/male ratio of 9:1.2 Although the incidence of PBC tiating event in the loss of tolerance primarily to mito- appears to be stable, the overall prevalence of the disease chondrial pyruvate dehydrogenase complex, E2, during is increasing.3 An individual’s genetic susceptibility, epige- which exogenous antigens evoke an immune response netic factors, and certain environmental triggers seem to that recognizes an endogenous (self) antigen inciting an play important roles.
    [Show full text]
  • Gastroesophageal Reflux Disease (GERD)
    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.
    [Show full text]
  • Non-Alcoholic Fatty Liver Disease
    Non-alcoholic fatty liver disease Description Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat. The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged. Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non- alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system.
    [Show full text]
  • In Patients with Crohn's Disease Gut: First Published As 10.1136/Gut.38.3.379 on 1 March 1996
    Gut 1996; 38: 379-383 379 High frequency of helicobacter negative gastritis in patients with Crohn's disease Gut: first published as 10.1136/gut.38.3.379 on 1 March 1996. Downloaded from L Halme, P Karkkainen, H Rautelin, T U Kosunen, P Sipponen Abstract In a previous study we described upper gastro- The frequency of gastric Crohn's disease intestinal lesions characteristic of CD in 17% has been considered low. This study was of patients with ileocolonic manifestations of undertaken to determine the prevalence of the disease.10 Furthermore, 40% of these chronic gastritis and Helicobacter pylori patients had chronic, non-specific gastritis. infection in patients with Crohn's disease. This study aimed to determine the prevalence Oesophagogastroduodenoscopy was per- of chronic gastritis and that of H pylori infec- formed on 62 consecutive patients suffer- tion in patients with CD who had undergone ing from ileocolonic Crohn's disease. oesophagogastroduodenoscopy (OGDS) at the Biopsy specimens from the antrum and Fourth Department of Surgery, Helsinki corpus were processed for both histological University Hospital between 1989 and 1994. and bacteriological examinations. Hpylori antibodies of IgG and IgA classes were measured in serum samples by enzyme Patients and methods immunoassay. Six patients (9.70/o) were During a five year period from September 1989 infected with H pylorn, as shown by histo- to August 1994, OGDS was performed on 62 logy, and in five of them the infection consecutive patients with CD to establish the was also verified by serology. Twenty one distribution of their disease. During the study patients (32%) had chronic H pyloni period, the OGDS was repeated (one to seven negative gastritis (negative by both times) - on three patients because of anaemia histology and serology) and one of them and on five patients because of upper gastroin- also had atrophy in the antrum and corpus.
    [Show full text]
  • An Unusual Case of Syphilis with Abdominal Pain
    Open Access Case Report DOI: 10.7759/cureus.16806 An Unusual Case of Syphilis With Abdominal Pain Mohsen Dourra 1 , Shiab Mussad 1 , Ana M. Capatina-Rata 2 1. College of Human Medicine, Michigan State University, East Lansing, USA 2. Internal Medicine, Ascension Providence Hospital - Southfield Campus, Southfield, USA Corresponding author: Mohsen Dourra, [email protected] Abstract Syphilis is a multisystem infection caused by Treponema pallidum, a common sexually transmitted bacterium. The different stages and associated signs of syphilis are well characterized. We present an atypical case of syphilis in a 27-year-old female with hepatitis and gastritis. The diagnostic criteria for syphilitic hepatitis and gastritis are discussed here, along with endoscopic and clinical findings, treatment, and a brief literature review. Categories: Internal Medicine, Gastroenterology, Infectious Disease Keywords: syphilis, gastroenterology, infectious diseases, hepatitis, sexually transmitted infections Introduction Syphilis cases have been resurging worldwide. In the United States, there were over 115,000 new cases from 2017 to 2018, according to the Centers for Disease Control and Prevention, especially in high-risk populations [1]. Uncommon presentations with hepatitis or gastritis may go unrecognized because it mimics many other pathological processes. This may lead to a delay in diagnosis and treatment. Patients with appropriate risk factors for syphilis should be considered for testing. Case Presentation A 27-year-old female presented to the hospital with a three-day history of fever, chills, vomiting, and right upper quadrant pain. She also complained of dark urine and diffuse myalgias and arthralgias. The patient had a medical history of well-controlled asthma. She was sexually active with only one male partner over the past year and was not using barrier protection.
    [Show full text]
  • Non-Alcoholic Fatty Liver Disease Information for Patients
    April 2021 | www.hepatitis.va.gov Non-Alcoholic Fatty Liver Disease Information for Patients What is Non-Alcoholic Fatty Liver Disease? Losing more than 10% of your body weight can improve liver inflammation and scarring. Make a weight loss plan Non-alcoholic fatty liver disease or NAFLD is when fat is with your provider— and exercise to keep weight off. increased in the liver and there is not a clear cause such as excessive alcohol use. The fat deposits can cause liver damage. Exercise NAFLD is divided into two types: simple fatty liver and non- Start small, with a 5-10 minute brisk walk for example, alcoholic steatohepatitis (NASH). Most people with NAFLD and gradually build up. Aim for 30 minutes of moderate have simple fatty liver, however 25-30% have NASH. With intensity exercise on most days of the week (150 minutes/ NASH, there is inflammation and scarring of the liver. A small week). The MOVE! Program is a free VA program to help number of people will develop significant scarring in their lose weight and keep it off. liver, called cirrhosis. Avoid Alcohol People with NAFLD often have one or more features of Minimize alcohol as much as possible. If you do drink, do metabolic syndrome: obesity, high blood pressure, low HDL not drink more than 1-2 drinks a day. Patients with cirrhosis cholesterol, insulin resistance or diabetes. of the liver should not drink alcohol at all. NAFLD increases the risk for diabetes, cardiovascular disease, Treat high blood sugar and high cholesterol and kidney disease. Ask your provider if you have high blood sugar or high Most people feel fine and have no symptoms.
    [Show full text]
  • Diet and Fatty Liver Disease
    10/15/2020 Diet and Fatty Liver Disease KRISTEN COLEMAN RD CNSC CRMC LIVER EXPO 2020 1 Fatty Liver Disease Importance of liver health and liver functions of digestion Fatty Liver Disease and Pediatrics Nutrition tips for a healthy liver Foods that cause Fatty Liver What foods to eat to with Fatty Liver Disease 2 1 10/15/2020 Liver Function Removes toxicants from the body Metabolizes / Digests protein, carbohydrates, and fat Glycogen Storage Controls / Regulates neuro-hormonal mechanisms 3 Fatty Liver and Children Fatty liver disease is the most common cause of chronic liver disease in children ◦ Simple Fatty Liver Disease – fat accumulated on live but no cell damage or inflammation ◦ Non-Alcoholic Steatohepatitis (NASH) – fat accumulation with inflammation and cell damage which can lead to cirrhosis or liver cancer Effects 1 in 10 kids ◦ Fatty liver disease in children has doubled in the last 20 years ◦ Why? ◦ Increase in pediatric obesity ◦ Poor nutrition ◦ Limited activity 4 2 10/15/2020 Fatty Liver and Children Children and Diet ◦ Fruit Juice, sports drinks, soda ◦ High carbohydrate snacks – crackers, chips ◦ High fructose corn syrup intake - fruit snacks, sugary yogurts, canned fruits, granola bars ◦ High intake of processed foods – chicken nuggets,- French fries ◦ Limited intake of fiber and water intake ◦ Grazing / frequent snacking Diet treatment for fatty liver in kids is the same as adults 5 How does diet effect/cause Fatty Liver? All carbohydrates are broken down into glucose Glucose travels though the blood stream and delivers energy to our cells If the cells do not need energy the glucose molecule is sent back to the liver for storage.
    [Show full text]
  • Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders
    Journal of Clinical Medicine Review Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders Cristiana Bianco 1 , Elena Coluccio 1, Daniele Prati 1 and Luca Valenti 1,2,* 1 Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] (C.B.); [email protected] (E.C.); [email protected] (D.P.) 2 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy * Correspondence: [email protected]; Tel.: +39-02-50320278; Fax: +39-02-50320296 Abstract: Anemia is a common feature of liver and bowel diseases. Although the main causes of anemia in these conditions are represented by gastrointestinal bleeding and iron deficiency, autoimmune hemolytic anemia should be considered in the differential diagnosis. Due to the epidemiological association, autoimmune hemolytic anemia should particularly be suspected in patients affected by inflammatory and autoimmune diseases, such as autoimmune or acute viral hepatitis, primary biliary cholangitis, and inflammatory bowel disease. In the presence of biochemical indices of hemolysis, the direct antiglobulin test can detect the presence of warm or cold reacting antibodies, allowing for a prompt treatment. Drug-induced, immune-mediated hemolytic anemia should be ruled out. On the other hand, the choice of treatment should consider possible adverse events related to the underlying conditions. Given the adverse impact of anemia on clinical outcomes, maintaining a high clinical suspicion to reach a prompt diagnosis is the key to establishing an adequate treatment. Keywords: autoimmune hemolytic anemia; chronic liver disease; inflammatory bowel disease; Citation: Bianco, C.; Coluccio, E.; autoimmune disease; autoimmune hepatitis; primary biliary cholangitis; treatment; diagnosis Prati, D.; Valenti, L.
    [Show full text]
  • Peptic Ulcer Disease
    \ Lecture Two Peptic ulcer disease 432 Pathology Team Done By: Zaina Alsawah Reviewed By: Mohammed Adel GIT Block Color Index: female notes are in purple. Male notes are in Blue. Red is important. Orange is explanation. 432PathologyTeam LECTURE TWO: Peptic Ulcer Peptic Ulcer Disease Mind Map: Peptic Ulcer Disease Acute Chronic Pathophysiology Morphology Prognosis Locations Pathophysiology Imbalance Acute severe Extreme Gastric Duodenal gastritis stress hyperacidity between agrresive and defensive Musocal Due to factors increased Defenses Morphology acidity + H. Pylori infection Mucus Surface bicarbonate epithelium barrier P a g e | 1 432PathologyTeam LECTURE TWO: Peptic Ulcer Peptic Ulcer Definitions: Ulcer is breach in the mucosa of the alimentary tract extending through muscularis mucosa into submucosa or deeper. erosi on ulcer Chronic ulcers heal by Fibrosis. Erosion is a breach in the epithelium of the mucosa only. They heal by regeneration of mucosal epithelium unless erosion was very deep then it will heal by fibrosis. Types of Ulcer: 1- Acute Peptic Ulcers ( Stress ulcers ): Acutely developing gastric mucosal defects that may appear after severe stress. Pathophysiology: All new terms mentioned in the diagram are explained next page Pathophysiology of acute peptic ulcer Complication of a As a reult of Due to acute severe stress extreme gastritis response hyperacidity Mucosal e.g. Zollinger- inflammation as a Curling's ulcer Stress ulcer Cushing ulcer Ellison response to an syndrome irritant e.g. NSAID or alcohol P a g e | 2 432PathologyTeam
    [Show full text]